LRMR - NASDAQ
Larimar Therapeutics, Inc.
$3.30
-3.0%Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
At a Glance
Live SnapshotLarimar Therapeutics, Inc. Fair Value Envelope
Owner Earnings Valuation Tool
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Historical Financial Data
Base year metrics used for projections
Projection Settings
Forecast period and terminal assumptions
DCF Valuation Summary
Calculation flow from present value to intrinsic value per share
Owner Earnings Projections
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$56.6M | -$28.3M | -$14.2M | -$7.1M | -$3.5M | -$1.8M | -$884.4K | -$442.2K | -$221.1K | -$110.5K |
| Maintenance CapEx | -$9.1K | -$4.6K | -$2.3K | -$1.1K | -$569 | -$284 | -$142 | -$71 | -$36 | -$18 |
| Owner Earnings | -$56.6M | -$28.3M | -$14.2M | -$7.1M | -$3.5M | -$1.8M | -$884.5K | -$442.3K | -$221.1K | -$110.6K |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$52.4M | -$24.3M | -$11.2M | -$5.2M | -$2.4M | -$1.1M | -$516.1K | -$238.9K | -$110.6K | -$51.2K |
Related Guides
Continue your LRMR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.